Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.00
$0.01
$0.00
▼
$0.14
$287K0.27636,162 shs1.11 million shs
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
$0.00
+26.1%
$0.00
$0.01
▼
$0.07
$333K0.4399,466 shs500,677 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$0.02
-8.0%
$0.72
$0.02
▼
$10.99
$363K1.1624.32 million shs121.84 million shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
-40.0%
$0.00
$0.00
▼
$0.01
$92K0.12234,261 shs654,448 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.00%-2.44%-23.08%-60.00%-93.33%
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
0.00%-35.56%-30.95%-70.56%-89.12%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
0.00%0.00%-95.54%-99.18%-99.73%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-40.00%0.00%-62.50%-62.50%-94.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.00
$0.01
$0.00
▼
$0.14
$287K0.27636,162 shs1.11 million shs
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
$0.00
+26.1%
$0.00
$0.01
▼
$0.07
$333K0.4399,466 shs500,677 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$0.02
-8.0%
$0.72
$0.02
▼
$10.99
$363K1.1624.32 million shs121.84 million shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
-40.0%
$0.00
$0.00
▼
$0.01
$92K0.12234,261 shs654,448 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.00%-2.44%-23.08%-60.00%-93.33%
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
0.00%-35.56%-30.95%-70.56%-89.12%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
0.00%0.00%-95.54%-99.18%-99.73%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-40.00%0.00%-62.50%-62.50%-94.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.00
N/AN/AN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
0.00
N/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.29
Hold$11.5071,775.00% Upside
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SRNE, KPTI, DIGP, and CERO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/2/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
DowngradeBuy ➝ Neutral
9/24/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
9/10/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
8/27/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/A($41.98) per shareN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
$2.70M0.12N/AN/A($0.03) per share-0.10
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$146.07M0.00N/AN/A($16.00) per share0.00
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-$8.30M-$0.74N/AN/AN/AN/AN/A-209.40%12/2/2026 (Estimated)
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
$250KN/AN/AN/AN/AN/AN/A-35.56%N/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$196.04M-$13.09N/AN/AN/A-153.28%N/A-145.18%N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/AN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/A
0.56
0.56
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
N/A
0.91
0.91
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
0.79
0.76
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
29.64%
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
N/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.36%
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
10.80%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
1.68%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
871.63 million1.05 millionN/A
Hypha Labs, Inc. stock logo
DIGP
Hypha Labs
20114.71 million102.32 millionNot Optionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
38022.68 million22.30 millionOptionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
949306.34 millionN/ANo Data

Recent News About These Companies

Why Is Sorrento Therapeutics (NASDAQ:SRNE) in Focus Today?
Sorrento Therapeutics Inc (SRNE) - Investing.com
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
Sorrento Therapeutics Inc (SRNE)
Sorrento Therapeutics
5 Sanders Cove, Sorrento WA 6020
Sorrento Therapeutics, Inc. (0L85.L)
Sorrento WA 6020
Sorrento Therapeutics Inc SRNEQ
29 Normanby Road Sorrento VIC 3943

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERo Therapeutics stock logo

CERo Therapeutics NASDAQ:CERO

$0.0040 0.00 (0.00%)
As of 11/19/2026 03:52 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Hypha Labs stock logo

Hypha Labs OTCMKTS:DIGP

$0.0029 +0.00 (+26.09%)
As of 11/13/2026

Hypha Labs, Inc., cultivates, produces, and sells psychedelic and functional mushroom in the United States. It has developed technology that quickly cultivates the mycelium root structures of psilocybin mushrooms and other functional mushroom's mycelium into a natural product. The company was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$0.02 0.00 (-8.05%)
Closing price 11/10/2026
Extended Trading
$0.02 0.00 (0.00%)
As of 11/10/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Sorrento Therapeutics stock logo

Sorrento Therapeutics OTCMKTS:SRNE

$0.0003 0.00 (-40.00%)
As of 11:24 AM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.